A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

Dose Finding Study to Assess the Efficacy and Safety of SK-PC-B70M in Patients With Mild to Moderate Alzheimer's Disease

The purpose of this study is to find optimistic dose and to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.

Inclusion Criteria:

• Age range : 50 ~ 85 years
• Clinical diagnosis of probable Alzheimer's disease (DSM-IV and NINCDS-ADRDA criteria)
• MRI within the last 12 months consistent with a diagnosis of AD
• MMSE score 10 to 26
• AChEI or memantine was discontinued at least 3 months prior to screening

Exclusion Criteria:

• Patient in mild cognitive impairment (MCI; CDR-SB <2.5)
• Other central nervous disease
• hypothyroidism, Vitamin B12/ Folic acid deficiency, hypercalcemia, neurosyphilis, AIDS
• T.I.A or Major infarction within the last 12 months
• Any serious disorder that could limit the ability of the patient to participate in the study
• COPD or asthma
• Any condition which would make the patient or the caregiver, in the opinion of the investigator, unsuitable for the study